The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland

被引:7
作者
Bochenek, Tomasz [1 ]
Kocot, Ewa [2 ]
Rodzinka, Marcin [3 ]
Godman, Brian [4 ,5 ]
Maciejewska, Katarzyna [3 ]
Kamal, Susan [6 ]
Pilc, Andrzej [7 ]
机构
[1] Jagiellonian Univ, Dept Drug Management, Fac Hlth Sci, Coll Med, PL-31531 Krakow, Poland
[2] Jagiellonian Univ, Hlth Econ & Social Secur Dept, Fac Hlth Sci, Coll Med, Krakow, Poland
[3] Jagiellonian Univ, Hlth Promot Dept, Fac Hlth Sci, Coll Med, Krakow, Poland
[4] Karolinska Inst, Div Clin Pharmacol, Stockholm, Sweden
[5] Strathclyde Univ, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland
[6] Univ Lausanne, Univ Geneva, Sch Pharmaceut Sci, Community Pharm Dept, Geneva, Switzerland
[7] Polish Acad Sci, Inst Pharmacol, Dept Neurobiol, Krakow, Poland
关键词
Health technology assessment; HTA; pharmaceutical reimbursement; public information; citizens' rights; transparency; Poland; RISK-SHARING ARRANGEMENTS; INVOLVEMENT; MEDICINES;
D O I
10.1080/14737167.2017.1262767
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The appropriate access to public information is very important for healthcare system stakeholders. The goal of this study was to examine how the execution of the formally existing right to public information on the HTA-based recommendations on reimbursement of new health technologies from public funds has been changing in Poland.Methods: All recommendations published within two predefined equal periods of time between 2013 and 2015 were analyzed. The gathered data was subjected to statistical analysis.Results: The frequency and intensity of censoring the published HTA-based recommendations on the pharmaceutical reimbursement has diminished. The text readability and clarity of message has improved, although the degree of decisiveness of the recommendations has dropped.Conclusion: The positive changes in the public communication policy should be continued. The transparency of the HTA-based recommendations should be increased further in some areas in the future.
引用
收藏
页码:385 / 400
页数:16
相关论文
共 50 条
[31]   Importance of Evidence-Based Health Insurance Reimbursement and Health Technology Assessment for Achieving Universal Health Coverage and Improved Access to Health in India [J].
Dang, Amit ;
Dang, Dimple ;
Vallish, B. N. .
VALUE IN HEALTH REGIONAL ISSUES, 2021, 24 :24-30
[32]   HEALTH TECHNOLOGY ASSESSMENT IN POLAND AND SCOTLAND: COMPARISON OF PROCESS AND DECISIONS [J].
Kolasa, Katarzyna ;
Wasiak, Radek .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (01) :70-76
[33]   A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal [J].
Rothwell, Joanne C. ;
Julious, Steven A. ;
Cooper, Cindy L. .
TRIALS, 2018, 19
[34]   A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal [J].
Joanne C. Rothwell ;
Steven A. Julious ;
Cindy L. Cooper .
Trials, 19
[35]   Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement [J].
Wang, Ting ;
McAuslane, Neil ;
Goettsch, Wim G. ;
Leufkens, Hubert G. M. ;
De Bruin, Marie L. .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2023, 39 (01)
[36]   R WE ready for reimbursement? A round up of developments in RWE relating to health technology assessment: part 2 [J].
Simpson, Alex ;
Ramagopalan, Sreeram, V .
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (13) :957-959
[37]   Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports [J].
Joost J. Enzing ;
Saskia Knies ;
Jop Engel ;
Maarten J. IJzerman ;
Beate Sander ;
Rick Vreman ;
Bert Boer ;
Werner B. F. Brouwer .
Cost Effectiveness and Resource Allocation, 20
[38]   Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports [J].
Enzing, Joost J. ;
Knies, Saskia ;
Engel, Jop ;
IJzerman, Maarten J. ;
Sander, Beate ;
Vreman, Rick ;
Boer, Bert ;
Brouwer, Werner B. F. .
COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2022, 20 (01)
[39]   Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe [J].
Krzysztof Piotr Malinowski ;
Paweł Kawalec ;
Wojciech Trąbka ;
Christoph Sowada ;
Guenka Petrova ;
Manoela Manova ;
Alexandra Savova ;
Pero Draganić ;
Juraj Slabý ;
Agnes Männik ;
Kristóf Márky ;
Zinta Rugaja ;
Jolanta Gulbinovic ;
Tomas Tesar ;
Marian Sorin Paveliu .
Orphanet Journal of Rare Diseases, 15
[40]   Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe [J].
Malinowski, Krzysztof Piotr ;
Kawalec, Pawel ;
Trabka, Wojciech ;
Sowada, Christoph ;
Petrova, Guenka ;
Manova, Manoela ;
Savova, Alexandra ;
Draganic, Pero ;
Slaby, Juraj ;
Mannik, Agnes ;
Marky, Kristof ;
Rugaja, Zinta ;
Gulbinovic, Jolanta ;
Tesar, Tomas ;
Paveliu, Marian Sorin .
ORPHANET JOURNAL OF RARE DISEASES, 2020, 15 (01)